Skip to main
  1. Stocks
  2. Merck
  3. Forecast
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 29%
Buy 48%
Hold 24%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is well positioned by its diversified portfolio, with Keytruda, Gardasil, vaccines, and animal health supporting resilient cash generation, while 53% of 2025 sales came from US human health. The positive outlook is anchored in the company’s ability to defend and expand Keytruda and Gardasil share despite competition, while stronger commercialization of Winrevair and Ohtuvayre could add meaningful revenue upside. Confidence is also reinforced by late-stage pipeline momentum, including positive oncology readouts such as sac-TMT and intismeran, which may help offset Keytruda’s 2028 loss of exclusivity and support a longer growth runway.

Bears say

Merck & Co is facing a tougher fundamental setup as 2027 is expected to be a strategic investment year with elevated R&D and SG&A, while legacy LOE pressures from Bridion, Januvia/Janumet, and Adempas are not being fully offset by Winrevair, Welireg, and Capvaxive. Keytruda remains the core profit engine, but its growth is slowing as the franchise nears peak penetration and approaches the year-end 2028 patent cliff, while international pricing pressure and higher German rebates further trim earnings power. With 3Q26 sales roughly in line excluding one-time items, the outlook remains pipeline-dependent, and the company’s 2027 EPS estimate of $8.55 versus Street $9.23 implies muted growth at a premium 17.1x valuation.

Merck (MRK) has been analyzed by 21 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 48% recommend Buy, 24% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Merck (MRK) Analyst Forecast & Price Prediction

Get the latest Merck (MRK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Merck (MRK)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 21 analysts, Merck (MRK) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $160.14, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $160.14, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Merck (MRK) Analyst Forecast & Price Prediction

Get the latest Merck (MRK) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Merck (MRK)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover MRK stock data and trends